Published in Arthritis Res Ther on April 10, 2006
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr (1967) 10.30
Voluntary strength and fatigue. J Physiol (1954) 8.77
Human skeletal muscle function: description of tests and normal values. Clin Sci Mol Med (1977) 4.71
Quantitation of central activation failure during maximal voluntary contractions in humans. Muscle Nerve (1996) 3.01
Motor-unit discharge rates in maximal voluntary contractions of three human muscles. J Neurophysiol (1983) 2.61
Normal muscle strength and fatigability in patients with effort syndromes. BMJ (1988) 2.46
JOINT DISTENSION AND REFLEX MUSCLE INHIBITION IN THE KNEE. J Bone Joint Surg Am (1965) 2.44
The contribution of reflex inhibition to arthrogenous muscle weakness. Clin Sci (Lond) (1984) 2.01
Clinical and experimental application of the percutaneous twitch superimposition technique for the study of human muscle activation. J Neurol Neurosurg Psychiatry (1986) 2.00
Intra-articular pressure in rheumatoid arthritis of the knee. 3. Pressure changes during joint use. Ann Rheum Dis (1970) 2.00
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Central and peripheral fatigue in sustained maximum voluntary contractions of human quadriceps muscle. Clin Sci Mol Med (1978) 1.74
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum (2005) 1.67
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
Fatigue of intermittent submaximal voluntary contractions: central and peripheral factors. J Appl Physiol (1985) (1986) 1.46
Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum (1997) 1.45
Polyneuropathy in juvenile dermatomyositis. J Rheumatol (1995) 1.42
Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med (1989) 1.40
"Semi-open" muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand (1979) 1.33
Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol (2000) 1.32
Muscle inactivation: assessment of interpolated twitch technique. J Appl Physiol (1985) (1996) 1.31
The syndrome of myasthenia and polymyositis with comments on therapy. Ann N Y Acad Sci (1971) 1.11
Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum (2000) 1.04
Human muscle fatigue: frequency dependence of excitation and force generation. J Physiol (1988) 0.95
Isokinetic and isometric muscle strength combined with transcutaneous electrical muscle stimulation in primary fibromyalgia syndrome. J Rheumatol (1991) 0.88
Myasthenia in patients with dermatomyositis: clinical, electrophysiological and ultrastructural studies. J Neurol Sci (1978) 0.86
Inflammatory myopathies: issues in diagnosis and management. Arthritis Care Res (1997) 0.85
Physical activity and disablement in the idiopathic inflammatory myopathies. Curr Opin Rheumatol (2003) 0.84
P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Altered energy utilization during exercise. Arthritis Rheum (1992) 0.77
Clinical symptoms in patients with myositis-an acquired metabolic myopathy? Curr Opin Rheumatol (2003) 0.77
Metabolic disturbances during short exercises in dermatomyositis revealed by real-time functional 31P magnetic resonance spectroscopy. Rheumatology (Oxford) (2004) 0.77
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 1.66
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab (2002) 1.14
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum (2008) 1.07
Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther (2011) 0.97
ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat (2013) 0.95
Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev (2013) 0.93
Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer. J Med Chem (2002) 0.92
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis (2007) 0.90
Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies? Curr Opin Rheumatol (2004) 0.89
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol (2008) 0.87
Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) (2010) 0.86
An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. Curr Opin Rheumatol (2009) 0.85
Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology (Oxford) (2011) 0.84
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) (2009) 0.82
Chronic low back pain-associated paraspinal muscle dysfunction is not the result of a constitutionally determined "adverse" fiber-type composition. Spine (Phila Pa 1976) (2004) 0.82
Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis (2011) 0.81
Association of an MHC class II haplotype with increased risk of polymyositis in Hungarian Vizsla dogs. PLoS One (2013) 0.80
Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) (2009) 0.80
The role of myokines in muscle health and disease. Curr Opin Rheumatol (2016) 0.79
Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol (2013) 0.79
Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD. Org Biomol Chem (2010) 0.78
Understanding the origin of non-immune cell-mediated weakness in the idiopathic inflammatory myopathies - potential role of ER stress pathways. Curr Opin Rheumatol (2015) 0.77
Between-days reliability of electromyographic measures of paraspinal muscle fatigue at 40, 50 and 60% levels of maximal voluntary contractile force. Clin Rehabil (2002) 0.76
Strategies for evaluating idiopathic inflammatory myopathy disease susceptibility genes. Curr Rheumatol Rep (2014) 0.75
Percutaneous endoscopic gastrostomy feeding--a life-saving intervention in SSc-myositis overlap with pharyngeal dysfunction. Rheumatology (Oxford) (2012) 0.75
Editorial: collaborative international research leads to new biomarkers for diagnosis and prediction of outcome in the idiopathic inflammatory myopathy spectrum. Curr Opin Rheumatol (2013) 0.75
Exploring new mechanisms of weakness-induction, further dissection of clinical phenotypes and identification of new biomarkers in the idiopathic inflammatory myopathies. Curr Opin Rheumatol (2015) 0.75